146 related articles for article (PubMed ID: 35548958)
41. [Risk factors for cardiotoxicity during fluorouracil and cisplatin combination chemotherapy].
Kaise M; Yoshino M; Nagai H; Sasaki S; Okura Y; Maruyama Y
Gan To Kagaku Ryoho; 2014 May; 41(5):601-4. PubMed ID: 24917005
[TBL] [Abstract][Full Text] [Related]
42. Cardiotoxicity of 5-flourouracil: two case reports.
Tutkun A; Inanli S; Caymaz O; Ayanoğlu E; Duman D
Auris Nasus Larynx; 2001 Apr; 28(2):193-6. PubMed ID: 11240331
[TBL] [Abstract][Full Text] [Related]
43. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment.
Rajaeinejad M; Parhizkar-Roudsari P; Khoshfetrat M; Kazemi-Galougahi MH; Mosaed R; Arjmand R; Mohsenizadeh SA; Arjmand B
Cardiovasc Toxicol; 2024 Feb; 24(2):184-198. PubMed ID: 38324115
[TBL] [Abstract][Full Text] [Related]
44. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk.
Lestuzzi C; Vaccher E; Talamini R; Lleshi A; Meneguzzo N; Viel E; Scalone S; Tartuferi L; Buonadonna A; Ejiofor L; Schmoll HJ
Ann Oncol; 2014 May; 25(5):1059-64. PubMed ID: 24558023
[TBL] [Abstract][Full Text] [Related]
45. Rare Presentation of Cardiotoxicity Related to 5-Fluorouracil.
Charkviani M; Murvelashvili N; Barrera F; Sharma A; Eldin RS; Nabil NUN
Case Rep Oncol Med; 2020; 2020():4151474. PubMed ID: 32774961
[TBL] [Abstract][Full Text] [Related]
46. The Role of Biomarkers to Evaluate Cardiotoxicity.
Upshaw JN
Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
[TBL] [Abstract][Full Text] [Related]
47. Cardiotoxicity of 5-fluorouracil.
Collins C; Weiden PL
Cancer Treat Rep; 1987; 71(7-8):733-6. PubMed ID: 3300968
[TBL] [Abstract][Full Text] [Related]
48. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen.
Cerny J; Hassan A; Smith C; Piperdi B
Clin Colorectal Cancer; 2009 Jan; 8(1):55-8. PubMed ID: 19203898
[TBL] [Abstract][Full Text] [Related]
49. The need for routine monitoring of cardiac function in patients receiving 5-fluorouracil infusion.
Francis N
Clin J Oncol Nurs; 2014 Jun; 18(3):360-2. PubMed ID: 24867118
[TBL] [Abstract][Full Text] [Related]
50. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
51. High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer.
Mokuyasu S; Suzuki Y; Kawahara E; Seto T; Tokuda Y
Breast Cancer; 2015 Nov; 22(6):563-9. PubMed ID: 24563373
[TBL] [Abstract][Full Text] [Related]
52. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
Cho H; Lee S; Sim SH; Park IH; Lee KS; Kwak MH; Kim HJ
Breast Cancer Res Treat; 2020 Jul; 182(2):333-343. PubMed ID: 32468335
[TBL] [Abstract][Full Text] [Related]
53. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Vater LB; Lefebvre B; Turk A; Clasen SC
Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
[TBL] [Abstract][Full Text] [Related]
54. Markers of Cardiotoxicity in Early Breast Cancer Patients Treated With a Hypofractionated Schedule: A Prospective Study.
De Sanctis V; Alfò M; Vitiello C; Vullo G; Facondo G; Marinelli L; Burocchi S; Gallo G; Valeriani M; Campanella B; Scalabrino G; Russo I; Salerno G; Cardelli P; Osti MF; De Biase L
Clin Breast Cancer; 2021 Jun; 21(3):e141-e149. PubMed ID: 33012660
[TBL] [Abstract][Full Text] [Related]
55. [Cardiotoxicity of 5-fluorouracil. Clinical relevance of palliative radiochemotherapy of malignant head-neck tumors].
Heib C; Schmidt HJ; Heib T; Lüer B; Stasche N
Laryngorhinootologie; 2001 May; 80(5):249-52. PubMed ID: 11417246
[TBL] [Abstract][Full Text] [Related]
56. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
Cianci G; Morelli MF; Cannita K; Morese R; Ricevuto E; Di Rocco ZC; Porzio G; Lanfiuti Baldi P; Ficorella C
Br J Cancer; 2003 May; 88(10):1507-9. PubMed ID: 12771913
[TBL] [Abstract][Full Text] [Related]
57. Chemotherapy and echocardiographic indices in patients with non-Hodgkin lymphoma: the ONCO-ECHO study.
Mizia-Stec K; Elżbieciak M; Wybraniec MT; Różewicz M; Bodys A; Braksator W; Gąsior Z; Gościniak P; Hryniewiecki T; Kasprzak J; Wojtarowicz A; Zdziarska B; Płońska-Gościniak E
Med Oncol; 2017 Dec; 35(1):14. PubMed ID: 29274027
[TBL] [Abstract][Full Text] [Related]
58. Cardiotoxicity of the antiproliferative compound fluorouracil.
Becker K; Erckenbrecht JF; Häussinger D; Frieling T
Drugs; 1999 Apr; 57(4):475-84. PubMed ID: 10235688
[TBL] [Abstract][Full Text] [Related]
59. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
60. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
